Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Alector, Inc. - Common Stock (NQ: ALEC )

1.700 +0.070 (+4.29%)
Streaming Delayed Price Updated: 11:58 AM EST, Jan 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Alector, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
Alector Reports on Recent Progress and Outlines Strategic Priorities for 2025
From Alector, Inc.
Via GlobeNewswire
Neurology-Focused Alector Downgraded On Failed Alzheimer's Study, BofA Securities Highlights Lack Of Catalysts
Alector's AL002 misses primary endpoint in Alzheimer's trial. BofA downgrades stock, cuts price target, and highlights near-term challenges. 
Via Benzinga
Wall Street's Top 10 Stock Calls This Week - Saturday, Nov. 30
Via Talk Markets
Topics Stocks / Equities
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Crude Oil Moves Lower; Dick's Sporting Goods Earnings Top Views
Via Benzinga
Exposures Fossil Fuels
Recap: Alector Q4 Earnings
Via Benzinga
Nasdaq Rises 100 Points; Abercrombie & Fitch Shares Fall After Q3 Results
Via Benzinga
Alector/AbbVie-Partnered Alzheimer's Drug Disappoints In Mid-Stage Study; Alector Lays Off 17% Of Workforce
Alector's AL002 fails in Phase 2 Alzheimer's trial, halting extension study; focus shifts to other programs as workforce is cut by 17%. 
Via Benzinga
US Stocks Mixed; Best Buy Posts Downbeat Earnings
Via Benzinga
Leslie's Posts Weak Results, Joins Zoom Video And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
Why Poseida Therapeutics Shares Are Trading Higher By 219%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Alector Announces Results from AL002 INVOKE-2 Phase 2 Trial in Individuals with Early Alzheimer’s Disease and Provides Business Update
From Alector, Inc.
Via GlobeNewswire
Alector Secures Flexible Credit Facility for Up to $50 Million From Hercules Capital
From Alector, Inc.
Via GlobeNewswire
Alector Reports Third Quarter 2024 Financial Results and Provides Business Update
From Alector, Inc.
Via GlobeNewswire
Alector Presents Baseline Characteristics for Pivotal INFRONT-3 Phase 3 Clinical Trial at the 14th International Conference on Frontotemporal Dementias (ISFTD 2024)
From Alector, Inc.
Via GlobeNewswire
Alector to Participate in Upcoming Healthcare Conferences
From Alector, Inc.
Via GlobeNewswire
Alector Reports Second Quarter 2024 Financial Results and Provides Business Update
From Alector, Inc.
Via GlobeNewswire
Alector to Host Mid-Year Earnings Conference Call
Call Scheduled for Wednesday, August 7, 2024, at 4:30 p.m. ET/1:30 p.m. PT 
From Alector, Inc.
Via GlobeNewswire
Alector Presents Baseline Characteristics for INVOKE-2 Phase 2 Clinical Trial of AL002 at the Alzheimer's Association International Conference® 2024 (AAIC®)
From Alector, Inc.
Via GlobeNewswire
Alector to Present Data on Pipeline Focus Areas at the Alzheimer's Association International Conference® (AAIC®) 2024
From Alector, Inc.
Via GlobeNewswire
Alector to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
From Alector, Inc.
Via GlobeNewswire
Perion Network Cuts Revenue Outlook, Joins Skye Bioscience And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
Alector to Host Virtual Research and Development Event Highlighting Alector Brain Carrier Blood-Brain Barrier Technology Platform
Leading scientific expert to provide insights into emerging technologies for blood-brain barrier modulation 
From Alector, Inc.
Via GlobeNewswire
Alector to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
From Alector, Inc.
Via GlobeNewswire
Alector to Participate in Upcoming Healthcare Conferences
From Alector, Inc.
Via GlobeNewswire
ALEC Stock Earnings: Alector Beats EPS, Beats Revenue for Q1 2024
ALEC stock results show that Alector beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Alector Reports First Quarter 2024 Financial Results and Provides Business Update
From Alector, Inc.
Via GlobeNewswire
Race To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback
The FDA has delayed making a decision on Eli Lilly's donanemab, pending an advisory committee meeting. 
Via Investor's Business Daily
Exposures Product Safety
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
We're starting Wednesday with a breakdown of the biggest pre-market stock movers traders will want to keep an eye on this morning! 
Via InvestorPlace
Alector to Participate in Upcoming Healthcare Conferences
From Alector, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.